期刊文献+

降钙素原在综合ICU的成本研究 被引量:1

Application of procalciton in comprehensive ICU
原文传递
导出
摘要 目的:分析ICU中抗生素在治疗感染患者时降钙素原(PCT)的成本及效果。方法:将112例感染者随机均分为2组,治疗组采用PCT指导法抗感染,对照组采用常规指导法抗感染,对2组抗感染治疗的直接医疗成本及效果进行评价。结果:2组的人均监测费用、指导抗菌启动时间、监测有效率差异有统计学意义(P<0.05或0.01),人均总成本、人均抗生素费用、继发真菌发生率、耐药菌发生率、副反应总发生率、治疗好转率、治疗恶化率等差异均无统计学意义。结论:PCT指导抗感染疗效较好,但是效果成本比低,从而无法取代效果成本高、疗效好的常规指导抗生素治疗的地位。 Objective:Analysis of the cost-effectiveness of procalcitonin(PCT)in the treatment of infected patients in ICU settings. Method: 112 cases were divided into two groups at random. The treatment group was treated according to the PCT guidance law against infection. The control group was treated according to conventional anti infective guidance. The direct medical cost of two groups and effect were evaluated and compared. Result: The monitoring cost per capita,start time of antibacterial guiding and monitoring efficiency had statistically significance (P〈0.05 or 0.01). The total cost per capita,cost of antibiotics per capita,the incidence of secondary fungus,incidence of drug-resistant bacteria, the total incidence, the treatment rate of deterioration had no statistical significance (P〈0.05). Conclusion:The effect of PCT guidance of anti-infection is good, but the cost-effectiveness was low.
出处 《临床急诊杂志》 CAS 2014年第7期410-413,共4页 Journal of Clinical Emergency
关键词 抗生素 成本效果分析 降钙素原 综合ICU antibiotics, cost - effectiveness analysis procalcitonin comprehensive ICU
  • 相关文献

参考文献10

二级参考文献47

  • 1姜辉,俞森洋.临床肺感染评分诊断通气机相关肺炎[J].中华医院感染学杂志,2005,15(7):751-752. 被引量:37
  • 2张媛,张鹏,吴尚为.耐万古霉素肠球菌耐药机制及实验室检测的研究进展[J].中华医院感染学杂志,2007,17(9):1178-1180. 被引量:27
  • 3Luna CM,Blanzaco D,Niederman MS,et al.Resolution of ventila-tor-associated pneumonia:prospective evaluation of the clinical pul-monary infection score as an early clinical predictor of outcome[J].Crit Care Med,2003,31:676-682.
  • 4Chris-Crain M,Jaccard-Stolz D,Bingisser R,et al.Effect ofprocalcitonin-guided treatment on antibiotic use and outcomein lower respiratory tract infection:cluster-randomised,sin-gle-blinded intervention trial[J].Lancet,2004,363:600-607.
  • 5Chris-Crain M,Stolz D,Bingisser R,et al.Procaicitonin guidan an-tibiotic therapy in community-acquired pneumonia:a randomizedtrial[J].Am J Respir Crit Care Med,2006,174:84-93.
  • 6Stola D,Christ C,Bingisser R,et al.Antibiotic treatment ofexacerbations of COPD,a randomized,controlled trial compa-ring procalcitonin-guidance with standard therapy[J].Chest,2007,131:9-19.
  • 7Briel M,Christ-Crain M,Young J,et al.Procalci tonin-guidedantibiotic use versus a standard approach for acute respiratorytract in fections in primary care:study protocol for a random-ized controlled trial and baseline characteristics of participatinggeneral practitioners[J].BMC Fam Pract,2005,6:34.
  • 8Beeker KL,Snider R,Nylen ES.Proealeition assay in systemicinflammation,infection,and sepsis:clinical utility and limita-tions[J].Crit Care Med,2008,36(3):941-952.
  • 9NOLLA SALAS J, SITGES SERRA A, LEON GIL C, et al. Can- didemia in non - neutropenic critically ill patients: analysis of prognostic factors andassessment of systemic antifungal therapy. Study group of fungal infection in the ICU [J]. Intensive Care Med, 1997, 23(1): 23-30.
  • 10UGARTE H, SILVA E, MERCAN D, et al. Procalcitonin used as a marker of infection in the intensive care unit[J]. Crit Care Med, 1999, 27(3) : 498 -504.

共引文献531

同被引文献10

引证文献1

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部